European Society of Gene and Cell Therapy Annual Congress (ESGCT) 30th Annual Congress

October 24 – 27, 2023
Brussels, Belgium
BOOTH: #19

We look forward to meeting you at ESGCT in Brussels. 

Request a meeting with our team to learn how we help our clients advance their drug modality.

Schedule a Meeting

Speak with our scientific experts onsite to discuss your project.

I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.



BioAgilytix Presentation at ESGCT

SESSION 8b: AAV, non-integrative vectors II

OR53: Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy

Presenter: Robert Nelson, PhD – Scientific Officer
Thursday, October 26th
15:00 - 17:00

About the event

ESGCT is an annual scientific meeting that brings together researchers and clinicians in the field of gene and cell therapy to share their latest findings, discuss new ideas, and collaborate on future projects. The convention covers a wide range of topics related to gene and cell therapy, including new technologies, clinical trials, and regulatory issues.

Partner with BioAgilytix for your gene and cell therapy project

Bioanalytical Experts for Advanced Therapeutic Medicinal Products

As the gene and cell therapy space continues to grow and new regulations are implemented by global agencies, finding CRO partners with the appropriate expertise and capabilities to support these preclinical and clinical programs is a critical component of success. Our scientific experts are thought leaders in the field with decades of combined experience across a wide range of gene and cell therapy products.

Since 2014, BioAgilytix has supported almost 300 unique gene therapy programs for more than 100 different sponsors and has partnered with our clients to support bioanalytical testing for over 80 individual cell therapy programs, including two that have received FDA-approval.

Our scientific teams are experienced across an array of platforms and assay types with the ability to work under nonregulated, GMP, GLP, GCP/GCLP, and CLIA conditions to meet your program needs. Common assays include:

  • Biodistribution (qPCR or ddPCR)
  • Persistence (qPCR, ddPCR, flow cytometry)
  • Vector Shedding (qPCR or ddPCR)
  • Total Antibody or Anti-Drug Antibody Assays (TAb or ADA)
  • Neutralizing Antibody Assays (NAb)
  • Cellular Immunogenicity (ELISpot)
  • Custom Biomarker Solutions
  • Product Release Testing (CMC)

Schedule a meeting with our experts onsite

Speak with our team about how the combination of world-class scientific expertise, outstanding project management, and superior regulatory insight can expedite your advanced therapeutic. You can also fill out the form, and an expert will reach out to schedule a meeting with you onsite.